Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise
Regulatory
Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director
Regulatory
Isofol presents at investor meetings in March
Non regulatory
Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin
Regulatory
Isofol Medical AB (publ) publishes year-end report, January – December 2025
Regulatory
Isofol participates in the ASCO GI congress
Non regulatory
Isofol participates in several investor meetings in December and January
Non regulatory
European Patent Office intends to grant a new patent for Isofol’s arfolitixorin
Non regulatory
Isofol Medical AB (publ) publishes interim report, January–September 2025
Regulatory
Isofol appoints nomination committee ahead of the Annual General Meeting 2026
Regulatory
Isofol invites to an investor meeting on November 13, 2025
Non regulatory
Isofol participates in the ESMO cancer congress
Non regulatory
Isofol’s clinical study with arfolitixorin reaches another important milestone
Non regulatory
Isofol completes transfer of shares to Solasia Pharma following a successful rights issue
Non regulatory
Isofol Medical AB (publ) publishes interim report, January–June 2025
Regulatory
